Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP +4.71%36 Net-Net Working Capital is $0.16 as of Mar. 2026. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 660 Consumer Packaged Goods companies, Integrated Biopharma ranks better than 95.3% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Integrated Biopharma's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $0.16.
The industry rank for Integrated Biopharma's Net-Net Working Capital or its related term are showing as below:
INBP's Price-to-Net-Net-Working-Capital is ranked better than 95.3% of 660
companies
in the Consumer Packaged Goods industry
Industry Median: 6.73
vs INBP: 1.05
Integrated Biopharma (OTCPK:INBP) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Integrated Biopharma Net-Net Working Capital Related Terms
Integrated Biopharma Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Integrated Biopharma's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrated Biopharma Net-Net Working Capital Chart
INBP vs HCWC, PAVS, BABB: Net-Net Working Capital Comparison
For the Packaged Foods subindustry, Integrated Biopharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma Price-to-Net-Net-Working-Capital vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.16 mean?
Integrated Biopharma (INBP) has a Net-Net Working Capital of $0.16 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Integrated Biopharma According to the industry distribution chart, Integrated Biopharma ranks #31 out of 660 companies in the Consumer Packaged Goods industry, placing it in the top 4.7%.
Is Integrated Biopharma's Net-Net Working Capital too high?
Integrated Biopharma's current Net-Net Working Capital is $0.16. The Consumer Packaged Goods industry median Net-Net Working Capital is 6.73. Integrated Biopharma's value of $0.16 is 97.6% below this industry median. Based on the distribution chart, Integrated Biopharma ranks #31 out of 660 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's Net-Net Working Capital compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #31 out of 660 companies for Net-Net Working Capital. This places Integrated Biopharma in the top 5% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 6.73. Integrated Biopharma's value of $0.16 is 97.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Consumer Packaged Goods company?
The median Net-Net Working Capital among Consumer Packaged Goods companies is 6.73, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Biopharma's current Net-Net Working Capital of $0.16 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Integrated Biopharma For the Consumer Packaged Goods industry, the median Net-Net Working Capital is 6.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current Net-Net Working Capital is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.17 — trading 35.4% below its estimated fair value. The current Net-Net Working Capital is $0.16 and 97.6% below the Consumer Packaged Goods industry median of 6.73. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current Net-Net Working Capital is $0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.17 is trading 35.4% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
Net-Net Working Capital: $0.16
GF Value™: $0.26 vs. price of $0.17 (35.4% below fair value)
Industry Position: 97.6% below the Consumer Packaged Goods median (#31 of 660)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
